Bio Green Med Solution (BGMS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
The 2026 Annual Meeting will be held virtually on June 18, 2026, allowing shareholders to attend, vote, and submit questions online, enhancing accessibility and reducing costs and environmental impact.
Shareholders will vote on the re-election of two Class I directors, ratification of the independent auditor, and an advisory vote on executive compensation.
The board unanimously recommends voting in favor of all proposals.
Only holders of common stock as of April 20, 2026, are entitled to vote; preferred stockholders are not eligible to vote on current proposals.
Voting matters and shareholder proposals
Proposals include: (1) election of Dr. Satis Waran Nair Krishnan and Inigo Angel Laurduraj as Class I directors for a three-year term, (2) ratification of SFAI Malaysia Plt. as independent auditors for 2026, and (3) advisory approval of executive compensation.
The board recommends a vote FOR each proposal.
Voting can be done online, by phone, mail, or during the virtual meeting using a 16-digit control number.
Shareholders may change or revoke proxies before the meeting.
Additional business may be considered if properly presented.
Board of directors and corporate governance
The board consists of five directors divided into three classes, with staggered three-year terms.
Board committees include Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.
Directors are expected to attend all meetings; in 2025, all current directors attended 100% of meetings.
The board values diversity in gender, ethnicity, and professional background.
Governance documents, including committee charters and the Code of Conduct, are available on the company website.
Latest events from Bio Green Med Solution
- Net loss narrowed to $3.0 million in 2025 as fire safety revenue reached $0.7 million.BGMS
Q4 202530 Mar 2026 - Lower Q2 loss and R&D spend, but cash runway and compliance risks persist.BGMS
Q2 20241 Feb 2026 - FADRA demonstrates durable responses in biomarker-driven cancer trials; PLOGO reformulation underway.BGMS
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Stockholders will vote on key proposals that could shift control and restructure the company's capital.BGMS
Proxy Filing2 Dec 2025 - Shareholders to vote on equity issuances, reverse split, and governance changes to secure funding.BGMS
Proxy Filing2 Dec 2025 - Shareholders to vote on equity issuances, reverse split, and governance changes to ensure compliance.BGMS
Proxy Filing2 Dec 2025 - Virtual annual meeting to vote on directors, equity plan amendment, and executive pay.BGMS
Proxy Filing2 Dec 2025 - Virtual meeting to vote on director elections, equity plan amendment, and executive pay.BGMS
Proxy Filing2 Dec 2025 - Key votes include share issuance, corporate name change, and governance amendments.BGMS
Proxy Filing2 Dec 2025